However, as mentioned above, targeted agents are used off-label in mainly solid pediatric neoplasms (e.g., Dasatinib, Trametinib), and, moreover, novel therapies are used in the fields of clinical trials (e.g., Regorafenib in Ewing sarcoma) and multi-target tyrosine kinase (and non-tyrosine kinase) receptors, including EPH/ephrin members [143,144,145]. The gene discussed is EPHA1; the disease is Ewing sarcoma.